Genetic and Epigenetic Intersections in COVID-19-Associated Cardiovascular Disease: Emerging Insights and Future Directions

Figures

• 

  Figure 1. The multi-step process of coronavirus infection that can lead to cardiovascular injury. Following infection, the virus induces RAAS (renin–angiotensin–aldosterone system) dysfunction, leading to inflammation and oxidative stress, especially in the kidneys. These events contribute to endothelial dysfunction, with the generation of reactive oxygen species (ROS) resulting in plaque deposition in coronary arteries. Concurrently, the immune system’s overreaction causes a cytokine storm, which further exacerbates cardiovascular stress. The combined effects of hypoxia and the imbalance between oxygen supply and demand aggravate the risk of cardiovascular injury.

• 

  Figure 2. How epigenetic modifications affect ACE2 expression and influence viral infection and cardiovascular disease (CVD) risk. Promoter hypermethylation downregulates ACE2, reducing the chance of viral infection, while promoter hypomethylation leads to ACE2 upregulation, increasing susceptibility to viral entry. This elevated risk can result in viral-induced cardiovascular diseases, completing a cycle where epigenetic factors shape both viral infection susceptibility and CVD progression.

• 

  Figure 3. The progression from viral infection to the development of atherosclerosis through immune system activation. The viral infection triggers immune cells to release cytokines like TNF-α and IL-6, promoting smooth muscle growth and vessel narrowing. Activated immune cells generate reactive oxygen species (ROS), which oxidize low-density lipoproteins (LDLs), leading to the formation of oxidized LDLs (OxLDLs). These OxLDLs activate platelets, resulting in platelet aggregation and the formation of plaque. The accumulation of these plaques contributes to the development of atherosclerosis, increasing the risk of cardiovascular disease.

• 

  Figure 4. The relationship between genetic and epigenetic markers in predicting cardiovascular disease (CVD) risk due to viral infections. Part A focuses on genetic markers like LDLR, PCSK9, and F5, highlighting specific mutations (SNPs: rs688, rs11591147, rs6025) that contribute to CVD risk. Part B showcases epigenetic factors such as DNA methylation and miRNA regulation (e.g., miR-133, miR-208), which influence gene expression related to inflammation and heart failure. The integration of genetic and epigenetic data facilitates screening and analysis to predict viral infection-induced CVD risk.

• 

  Figure 5. The six genetic predispositions between COVID-19 infection and cardiovascular disease (CVD). The figure highlights specific genes such as TLR7, UNC13D, DES and SPEG, LZTFL1, ABO, ILRUN, and CACFD1, detailing how mutations in these genes increase susceptibility to severe COVID-19 symptoms and related cardiovascular complications. Genetic variations in these genes contribute to immune dysregulation, cytokine storms, hypercoagulability, and inflammation, all of which elevate the risk of developing conditions like cardiomyopathy, heart failure, and thrombosis in COVID-19 patients.

• 

  Figure 6. The integration of genomic and epigenomic data utilizing genome-wide association studies (GWASs) and epigenome-wide assoiation studies (EWASs) to identify cardiovascular disease (CVD) risk factors upon viral infection. GWASs detect genetic variants like SNPs in genes such as ACE2 and PCSK9, while EWASs focus on epigenetic changes, like DNA methylation, influencing gene expression. The combination of these data enables personalized therapies by screening genetic and epigenetic profiles, aiming to predict and mitigate CVD risks such as atherosclerosis, myocarditis, and heart failure in the context of viral infections.